Auditory, visual and tactile hallucinations in a 16-year-old adolescent with high-dose duloxetine at one time

Öz

Duloxetine is a dual-acting serotonin-noradrenaline reuptake inhibitor. It has FDA approval for the diagnosis of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Neuropathic Pain, Fibromyalgia, Chronic Skeletal Muscle Pain in adults, and GAD in children and adolescents. This article presents a 16-year-old female patient referred to the emergency department with hallucinations starting after she took a total of 330 mg/day duloxetine for headaches. It is thought that her experienced hallucinations may be due to increased dopamine, as a result of inhibition of serotonergic system and noradrenaline transport system. It is thought that this article will contribute to the literature in terms of pharmacokinetic and pharmacodynamic effects of duloxetine in children and adolescents.

Anahtar Kelimeler

• Duloxetine,Hallucination,Adolescent

16 yaşındaki ergende tek seferde yüksek doz duloksetin kullanımı ortaya çıkan işitsel, görsel ve dokunsal halüsinasyonlar

Öz

Duloksetin dual etkili serotonin-noradrenalin geri alım inhibitörüdür. Erişkinlerde Major Depresif Bozukluk (MDD), Yaygın Anksiyete Bozukluğu (GAD), Diyabetik Nöropatik Ağrı, Fibromiyalji, Kronik İskelet Kas Ağrısı tanılarında, çocuk ve ergenlerde GAD için FDA onayı vardır. Bu yazıda, baş ağrıları olduğu için toplam 330 mg/gün duloksetin içen sonrasında halüsinasyonları başladığı için acil servise başvuran 16 yaşındaki kadın hasta sunulacaktır. Halüsinasyonların serotonerjik sistem ve noradrenalin transport sisteminin inhibisyonu sonucunda dopamin artışına bağlı olabileceği düşünülmektedir. Bu yazı, duloksetinin, çocuk ve ergenlerdeki farmakokinetik ve farmakodinamik etkileri açısından literatüre katkı sağlayacağı düşünülmüştür.

Anahtar Kelimeler

• Duloksetin,Halüsinasyon,Ergen

Kaynakça

1. 1. Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opinion on Drug Safety. 2005.
2. 2. FDA. Cymbalta (duloxetine hydrochloride) capsules. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf. Accessed 1 Sep 2019.
3. 3. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. Journal of Child and Adolescent Psychopharmacology. 2012.
4. 4. Lobo ED, Quinlan T, Prakash A. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. Clinical Pharmacokinetics. 2014.
5. 5. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of Clinical Psychopharmacology. 2007.
6. 6. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo adverse drug reactions probability scale. Psychiatry and Clinical Psychopharmacology. 2017;27:205–6.
7. 7. Emslie GJ, Wells TG, Prakash A, Zhang Q, Pangallo BA, Bangs ME, et al. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology. 2015.
8. 8. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012.

9. 9. Birmaher B, Brent D. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2008.
10. 10. Rolma G, Jelcic N, Gnoato F, Cecchin D, Cagnin A. Combined duloxetine and benzodiazepine-induced visual hallucinations in prodromal dementia with Lewy bodies. General Hospital Psychiatry. 2013.
11. 11. Tomita T, Yasui-Furukori N, Kaneko S. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder. Clinical Neuropharmacology. 2013.
12. 12. Gündüz N, Eren F, Turan H, Akbey Z. Visual and tactil hallucinations after duloxetine use: a case report. Anatolian Journal of Psychiatry. 2017.
13. 13. Yazici KU, Percinel Yazici I. Visual hallucination induced by duloxetine use: a male case diagnosed with generalized anxiety disorder. Psychiatry and Clinical Psychopharmacology. 2018.
14. 14. Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: Both dopamine and norepinephrine increase in prefrontal cortex. Journal of Clinical Psychiatry. 2003.
15. 15. Jacob MK, Ash P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy. Journal of Clinical Psychiatry. 2009.
16. 16. Lai CH. Escitalopram-related visual and auditory hallucination in a non-dementia patient with depression. Journal of Neuropsychiatry and Clinical Neurosciences. 2012.
17. 17. Schuld A, Archelos JJ, Friess E, Bourgeois JA. Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: Is the sigma receptor involved? (multiple letters). Journal of Clinical Psychopharmacology. 2000.
18. 18. Webb A, Cranswick N. Fluoxetine induced auditory hallucinations in an adolescent. Journal of Paediatrics and Child Health. 2003